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ABSTRACT 
Background and aim 
The aim of the study was to characterize ESBL-producing uropathogenic Escherichia coli 
(UPEC) strains isolated in children. That included the investigation of virulence factors and 
the analysis of the types of β-lactamases at the molecular genetic level.  
Material and methods 
During the two-year study period, 77 ESBL-producing E. coli strains were recovered from 
urine samples of febrile children with significant bacteriuria hospitalized at one Croatian 
hospital. Susceptibility of isolates to bactericidal serum activity was tested by Shiller and 
Hatch method, while adhesin expression was determined by agglutination methods. 
Characterization of ESBLs was performed by PCR with specific primers for ESBLs and by 
sequencing of blaESBL genes. Genotyping of the E. coli isolates was performed by pulsed-field 
gel electrophoresis (PFGE).  
Results 
Twenty-seven (35.1%) and 50 (64.9%)  ESBL-producing UPEC strains were isolated in 
neonates and infants, respectively. Of 70 strains investigated for the presence of virulence 
factors, adhesins were detected in 48.6% strains (8.6% in the neonate and 40% in the infants 
group) giving a statistically significant difference in adhesin expression between the two 
groups (p<0.01). Hemolysin was produced by 84.3%, whereas 70% of strains were serum-
resistant. The blaTEM gene was detected in 22 (28%) and blaSHV gene in 57 strains (74%), 
whereas blaCTX-M gene was detected in only two isolates (2.5%). In ten isolates, blaTEM and 
blaSHV were simultaneously detected. Sequencing of blaSHV genes revealed that SHV-5 β-
lactamase was by far the most prevalent and was found in 51 strains (66%). The strains were 
clonally related as demonstrated by PFGE and assigned into ten clusters. 
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Conclusions 
Infection control measures should be employed and the consumption of expanded-spectrum 
cephalosporins in the hospital should be restricted. 
 
KEY WORDS: Escherichia coli, virulence, urinary tract infections, children, extended-
spectrum β-lactamases  
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INTRODUCTION 
 Extended-spectrum β-lactamases (ESBL) producing bacteria have been increasingly reported 
in pediatric patients.  Production of ESBLs is the major mechanism of resistance to oxymino-
cephalosporins and aztreonam in Gram-negative bacteria [1-2]. ESBLs are predominantly 
derivatives of plasmid-mediated TEM or SHV β-lactamases and arise through mutations that 
alter the configuration of the active site, thereby expanding the hydrolytic spectrum of the 
enzyme [2]. Both TEM and SHV ESBLs are distributed worldwide with lots of variants 
described (data are available at http://www.lahey.org/studies/), and are mostly found in 
Enterobacteriaceae species like Klebsiella pneumoniae and Escherichia coli. Recently a new 
family of ESBLs with predominant activity against cefotaxime (CTX-M β-lactamases) has 
been reported [3]. In contrast to TEM or SHV-ESBLs CTX-M β-lactamases are native ESBLs 
and are derived from the chromosomal β-lactamases of the genus Kluyvera [4-5].  Over 50 
CTX-M enzymes have been described so far, which can be grouped into five main subgroups 
according to amino acid sequence identity (CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9 and 
CTX-M-25) [6].  Most CTX- M β-lactamases hydrolyze cefotaxime better than ceftazidime, 
but some of them such as CTX-M-15 hydrolyze also ceftazidime efficiently [6]. In some 
countries CTX-M β-lactamases are the most prevalent types of ESBLs, for instance in Russia 
[7], Greece [8], Spain [9], Switzerland [6], Japan [10], Taiwan [11], China [12] and Argentina 
[13]. ESBL producing Enterobacteriaceae are described with increasing frequency as 
causative agents of urinary tract infections (UTIs) [14-17]. E. coli is the most frequent cause 
of UTIs, and the probability of UTI depends on the virulence of the infecting bacteria and the 
susceptibility of the host. Factors described as virulence factors for uropathogenic E. coli 
(UPEC) are adherence ability, hemolysin, aerobactin and cytotoxic necrotizing factor type 1 
production, resistance to the bactericidal action of normal human serum and to phagocytosis 
[18].   
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The aim of present study was to characterize ESBL-producing UPEC isolated in children over 
a 2-year period at the Split University Hospital, Croatia, and to determine the possible 
differences in the characteristics of strains isolated in neonates and older children. The 
virulence factors of the strains were determined, and the prevalence of different types of 
ESBLs among those strains was investigated. ESBLs were characterized genetically and 
clonal relatedness of the strains was assessed thereby allowing the molecular epidemiology of 
the ESBL-producing E. coli strains. 
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MATERIAL AND METHODS 
Patients 
From January 2002 until December 2003 urine samples were collected from all children with 
symptoms of urinary tract infection or febrile neonates and infants with suspected UTI. Out of 
530 children with significant bacteriuria and E. coli in pure culture (>10
5
CFU/ml) and pyuria 
(>5 white blood cells/high power field), in 77 ESBL-positive E. coli was detected. There were 
two groups of children with ESBL-positive strain: 26 neonates (up to one month old) 
hospitalized at neonatology unit and 51 older children (infants from one month to one year 
old) hospitalized at paediatric unit. All urine samples in neonates and infants were obtained 
by urine bag collection, only urine samples in older children, in which ESBL strains were not 
detected, were collected by mid stream urine.  
Bacteria 
The ESBL-positive E. coli isolates were collected prospectively from febrile neonates and 
infants with significant bacteriuria with E. coli in pure culture and pyuria. The species were 
identified by conventional biochemical testing. All 77 uropathogenic ESBL-producing E. coli 
isolates were further analyzed in this study. 
Bacterial adhesins determination 
The expression of adhesins was defined by hemagglutination and inhibition of hemagglutination 
in microtiter plates, as previously described [18]. Briefly, hemagglutination (HA) was performed 
using human erythrocytes and sheep, ox and guinea pig erythrocytes. Inhibition of HA was 
performed with P1 antigen-containing pigeon egg white and with D-mannose (Sigma Chemical 
Co., St. Louis, USA), as previously described [19]. Isolates were considered to express P-
fimbriae if HA was positive with human erythrocytes and inhibition of HA was positive with 
pigeon egg white, which was confirmed by agglutination of receptor-coated latex beads. The type 
1 fimbriae were considered to be expressed if HA was positive with guinea pig erythrocytes. D-
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mannose  inhibits HA of guinea pig erythrocytes (mannose sensitive, MS HA), but it never does 
with human, ox or sheep erythrocytes (mannose resistant, MR HA). An isolate displaying MR 
HA was considered to express X adhesin when P-specificity was not detected. 
Determination of hemolytic activity 
The production of α hemolysin was tested on human blood agar plate and was considered 
positive when bacteria were stabbed with a sterile straight wire into 5% human blood agar, and 
after 18 to 24 h of incubation at 37 ºC, a clearing zone was observed.  
Sera and serum sensitivity assay 
Blood was obtained by venipuncture from three healthy volunteers and was allowed to clot at 
room temperature for 30 min and overnight at 4
o
C. After centrifugation at 1000 g for 15 min at 
4
o
C, serum was removed and pooled. A portion of the pooled serum was decomplemented by 
heating at 56
o
C for 30 min and used as test controls. Bacterial susceptibility to serum killing was 
measured by assessing regrowth after incubation in normal human serum according to Schiller 
and Hatch method [20]. 
Susceptibility to antibiotics 
 Antibiotic susceptibilities were determined by broth microdilution method according to the 
most recent CLSI criteria [21].  The concentrations of antibiotics which inhibited 50 and 90% 
of the strains (MIC50 and MIC90) and percentage of resistant strains were calculated. method.  
E. coli ATCC 25922 and K. pneumoniae ATCC 700603 used as quality control strains [22].  
Detection of extended-spectrum β-lactamases  
ESBL production was determined by double-disk synergy test (DDST) [23] and confirmed by 
at least threefold reduction in ceftazidime  (MIC) by clavulanate.  For DDST, an overnight 
broth culture of test strain was diluted in saline, adjusted to McFarland standard suspension 
0.5 and inoculated onto MH agar. Disk containing amoxycillin/clavulanate (co-amoxiclav) 
(20/10 µg) was placed in the middle of the plate and surrounded by disks containing 
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ceftazidime, cefotaxime, ceftriaxone and aztreonam (30 µg) at  distance of 2.5 cm (edge to 
edge). Plates were incubated overnight at 37ºC. Distorsion of the inhibition zones around 
cephalosporine disks towards co-amoxiclav disk was indicative of ESBL production. K. 
pneumoniae ATCC 70068 used as a positive control strain.  
Transfer of resistance determinants  
Conjugation experiments were set up employing E. coli A15 R-strain which is free of 
plasmids and resistant to rifampicin [24]. Overnight BHI (Brain-Heart Infusion, Difco Lab., 
Detroit, MI, USA) broth cultures of donor E. coli strains and E. coli recipient strain were 
mixed in the ratio 1:2 in 5 ml BHI broth and incubated 18 h at 37°C without shaking. 100 µl 
of the mating mixture was seeded on the MH plates containing ceftazidime (1 mg/L), 
rifampicin (256 mg/L) and combined plates containing ceftazidime+rifampicin.  
Transconjugants were selected on the combined plates containing ceftazidime (1 mg/L) and 
rifampicin (256 mg/L). The frequency of conjugation was expressed relatively to the number 
of donor cells. 
Characterization of extended-spectrum β-lactamases 
The presence of blaTEM, blaSHV, blaCTX-M genes and blaPER-1 genes was determined for E. coli 
strains by polymerase chain reaction (PCR) using primers and conditions as described 
previously  [25-28]. In brief, bacterial DNA was extracted by boiling and applied to PCR-
amplification using Taq polymerase (Invitrogen, Germany) under the following conditions: 
94°C for 5 min, 35 cycles consisting of 95°C for 30s, 55°C for 30s, and 72°C for 50s each, 
followed by a final extension at 72°C for 8 min. Primers used in this studies are shown in 
Table 1 [25-28].  The PCR products were detected by agarose gel electrophoresis after 
staining with ethidium bromide. PCR products obtained with primers specific for SHV β-
lactamases were subjected to PCR Nhe test [25] to distinguish between SHV-1 and SHV-
ESBL. Strains positive for CTX-M β-lactamases were tested further with specific primers for 
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groups 1, 2, 8 9 and 25 as described previously in order to amplify the whole coding sequence 
[29]. Amplicons were then column purified using Nucleo Spin Extract II (Machery-Nagel, 
Germany). Purified PCR products were sent to Medigenomix (Martinsried, Germany) for 
sequencing using an automated ABI3700 sequencer and the respective forward and reverse 
primers of the PCR amplification..  Designation of bla genes based on identified mutations 
was done according to the summary provided by the website of the Lahey Clinic 
(http://www.lahey.org/studies/). Lysates from reference strains producing TEM-1, TEM-2, 
SHV-1, SHV-2, SHV-3,  SHV-4, SHV-5, PER-1 and CTX-M-15 were used as positive 
controls for PCR.  
Characterization of plasmids 
Plasmids were extracted with Qiagen Plasmid Mini kit (QIAGEN Hamburg, Germany) 
according to manufacturer’s recommendations, from 17 strains which produced 
transconjugants in the mating experiments, run in 0.7% agarose gel, and stained with ethidium 
bromide. E. coli NTCC 50192 yielding four bands of know sizes of 148, 64, 36 and 7 kb was 
used as positive control. Plasmids were digested with EcoR1 restriction endonuclease.  
Molecular typing by pulsed-field gel electrophoresis (PFGE) of bacterial DNA 
PFGE of Xba-digested genomic DNA was performed with a CHEF-DRIII system (Bio-Rad, 
Hercules, CA, USA) as described previously [30]. The images were processed using the Gel-
Compare software, and a dendrogram was computed after band intensity correlation using 
global alignment with 2% optimization and UPGMA (unweighted pair-group method using 
arithmetical averages) clustering [31]. Cluster analysis of the Dice similarity coefficients 
based on the UPGMA using arithmetic averages was done to generate a dendrogram 
describing the relationship among E. coli genotypes. Isolates were considered to be identical 
if they showed 100% similarity and were considered clonally related if they showed greater 
than 80% similarity  
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Statistical methods 
Proportions were compared by the χ
2
-test and by Fisher's exact test respectively when the 
number in any of the 2x2 table was ≤5. A p-value <0.01 was considered statistically 
significant. 
 
RESULTS 
Prevalence of uropathogenic ESBL isolates 
From January 2002 until December 2003, 661 E. coli isolates were recovered from children 
treated in pediatric units (pediatrics, neonatology) at the Split University Hospital. A total of 
530 (80.18%) were isolated from urine in significant number (≥10
5
 bacteria per ml) from 
febrile children with pyuria. 
The proportion of ESBL-positive E. coli found in pediatric/neonate units during the 2-year 
period was 17% (114/661). The prevalence of uropathogenic E. coli producing ESBLs in 
febrile children with significant bacteriuria and pyuria was 14.5% (77/530).  These 77 
uropathogenic ESBL-producing strains were subjected to further analysis. During the study 
period there were 453 ESBL-negative E. coli strains isolated from children with significant 
bacteriuria and pyuria. 
Clinical data 
Twenty six patients were hospitalized in neonatology unit (children younger than one month) 
and 51 in paediatic unit (children older than one month). Gender data were available for 54 
children. Female/male ratio was 2:1. A total of 27 (35.1%) and 50 (64.9%) of ESBL-
producing E. coli strains were isolated from urine of 77 neonates and infants with diagnosed 
urinary tract infection, respectively. Since the children with ESBL-positive strains were all 
neonates or infants it was difficult to obtain information on symptoms of urinary tract 
infections because in this age the children cannot verbalize their symptoms.  
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Of the 77 patients providing strains for this study complete clinical data were available for 35 
patients. Clinical data are summarized in Table 2. There were several risk factors associated 
with UTIs. Eleven children were diagnosed with malformations of the urinary tract, seven 
females and four males (five with reflux, two with ureter stenosis, two with pyelon et ureter 
duplex, one with ren arcuatus and one with other malformation of the kidney). Additional two 
were low-birth-weight infants, while one was premature-delivered. For other 24 patients no 
risk factor for urinary tract infection was determined, as shown in Table 2.  In all except 8 
cases the UTIs were nosocomially acquired. The patients were treated with antibiotics. 
Fourteen patients received cefuroxime alone or combined with another beta-lactam. Sixteen 
patients were treated with ampicillin combined with netilmicin, gentamicin, ceftazidime or 
meropenem. Two patients received only meropenem, two ceftriaxone with vankomicin and 
one only sulphamethoxazole. The patients responded to the therapy. Only one patient with 
hydronephrosis caused by ureter stenosis ended up with nephrectomy, but the operation was 
not indicated because of urinary tract infection. In five patients ESBL positive E. coli 
persisted after completition of therapy. One of them received 
sulphamethoxazole/trimethoprim, one cefuroxime and the other three had combined therapy 
which included ampicillin combined with netilmicin and either   ceftazidime or co-amoxiclav.  
Characterization of virulence factors 
Of 70 strains investigated for the presence of virulence factors adhesins were detected in 34 
(48.6%) strains, six in neonate and 28 in infants group, and difference in adhesin expression 
between the two groups was statistically significant (χ
2
=9.20, p<0.01). P-fimbriae were 
detected in 14 strains, and only two of them were neonatal urine samples. Hemolysin was 
produced by 59 (84.3%) strains (24 in neonates and 35 in older children), whereas 49 (70%) 
strains were resistant to serum bactericidal activity (18 in neonate and 31 in infants group); 
the difference in hemolysin production and serum sensitivity of the strains between the two 
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groups was not statistically significant (p>0.05, χ
2
=1.16 and 0.03, respectively). Out of 14 P-
fimbriated strains, the blaTEM-1 gene was detected in 10 strains, while strains without this bla 
gene expressed this adhesin only rarely (χ
2
=19.68, p<0.01). 
Antibiotic susceptibilities 
 According to the most recent CLSI criteria of bacterial drug susceptibility 92% of the isolates 
were resistant to gentamicin and, 74% to netilmicin. No resistance  was observed to 
ciprofloxacin and carbapenems  (Table 3). The susceptibility to β-lactam antibiotics except of 
carbapenems is not mentioned because according to the CLSI they are not recommended for 
the therapy. All except two strains (36, 86) displayed the so called “CAZ phenotype” meaning 
that the resistance was more pronounced to ceftazidime and aztreonam than to cefotaxime and 
ceftriaxone. 
Conjugation 
 Twenty- three out of 77 strains transferred ceftazidime resistance to E. coli recipient. 
Resistance to tetracycline was co-transferred alongside with ceftazidime resistance from 18 
and to aminoglycosides from 16 strains. Resistance to cloramphenicol and cotrimoxazole was 
co-transferred from only one strain. 
Characterization of ESBLs 
 All ESBL-producing E. coli strains were tested for the presence of blaTEM, blaSHV, blaCTX-M 
and blaPER genes by PCR. Twenty two isolates (28%) yielded an amplicon with the TEM 
primers,  57 isolates (74%) with the SHV primers but only two isolates (2.5%) with the CTX 
primers.  The latter two possessed an IS26 insertion sequence.  In ten isolates, blaTEM and 
blaSHV were simultaneously detected. No blaPER-1 genes were detected by PCR. In six isolates 
no bla-encoding genes were identified with the PCR assays applied.  There was no 
statistically significant difference in bla gene detection between the neonate and older 
children groups (p>0.05).  
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SHV-type ESBL were identified by sequencing as SHV-5 in 51 isolates (66%), SHV-2 in 
three isolates (4%), SHV-2a in two strains (2.6%), and SHV-12 in one isolate (1.3%). 
Sequencing of TEM-type ESBLs yielded TEM-1 in 17 isolates (22%), TEM-2 in three 
isolates (4%), and TEM-116 and TEM-E2 in one isolate each (1.3%).  In one isolate, TEM-1 
and TEM-2 were simultaneously present. CTX-M-type ESBLs corresponded to CTX-M-3 β-
lactamase in both cases.  
Characterization of plasmids 
 SHV-5 β-lactamase has been encoded on different large plasmids. The strains contained one 
to ten plasmid bands. Transonjugants displayed similar plasmid profiles as their respective 
donors. Ten different restriction profiles were observed.  
Genotyping by PFGE 
 According to their genetic relatedness they were assigned into ten clusters (I to X) as shown 
in Figure 1. Several outbreaks with ESBL producing E. coli strains were identified in the 
study period. The first outbreak was caused by a clone referred to as clone I-1 represented by 
isolates 1, 5 and 6, the second one by a clone represented by isolates 9 and 10; both clones 
contained TEM-1 producing isolates. Further outbreaks were caused by clones I-3 (isolates 
76, 81, 83, I-4 (isolates 68, 69), II-1 (isolates 40, 41, 42, 43, 89), II-2 (isolates 38, 44),  II-3 
(isolates 92, 93, 95), II-4 (isolates 65, 67), II-5 (isolates 61,62),  III-1 (isolates 30, 33, 34, 35, 
53), III-2 (isolates 26, 27), III-3 (isolates 58, 60), III-4 (isolates 55,56) IV-1 (isolates 19, 20), 
IV-2 (isolates 23, 24), IV-3 (isolates 14, 15), IV-4 (isolates 17,18), and finally VI-1 (isolates 
70, 72). These outbreaks involved SHV-5 β-lactamase producing isolates except isolates of 
subcluster IV-3 which lost their resistance. The other isolates could not be assigned to genetic 
clones.  
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DISCUSSION 
The aim of this investigation was a comprehensive characterization of ESBL-producing 
UPEC strains detected with increasing frequency in neonate and pediatric units over 2-year 
period in a Croatian university hospital. There are many reports on ESBLs in 
Enterobacteriaceae, but this study differs from previous because it describes molecular 
epidemiology of ESBL-producing uropathogenic E. coli isolates in children in relatedness to 
the virulence characteristics of the strains.  
The first goal of the study was to characterize the uropathogenic ESBLs at the molecular 
genetic level and to identify possible breakouts. The proportion of ESBL found in 
pediatric/neonate units during the 2-year period was 17% which is much higher than in South 
America (1.7%) [5] and Poland (13%) [32], but lower than in Korea (25%) [33]. The overall 
proportion of ESBL producing E. coli in all hospital units from both adults and children 
during the study period was 4.51% (143/3164) [34].  It is higher than in Italy (1.2%) and most 
other European countries [35-36]. but lower than in China (34%) [37],  South America (25%) 
[38] and Turkey (9%) [39]. Much higher proportion of ESBLs in the study population 
compared to the overall proportion in the hospital could be explained by the spread of 
clonally related strains only in the pediatric hospital units.  
SHV-5 was found to be the predominant type of extended-spectrum β-lactamase. Some 
isolates harboured also and additional TEM-1 β-lactamase. SHV-5 β-lactamase is widespread 
in Middle and East Europe and has been previously described in Austria [40], Germany [41], 
Hungary [42], Poland [43], Greece [44], Bosnia and Herzegovina [16], Mexico  [45] and 
many other countries in the world. The resistance phenotype of the isolates is consistent with 
SHV-5 β-lactamase (high level ceftazidime resistance in most strains).  The presence of 
additional TEM-1 β-lactamase in some isolates could be responsible for resistance to co-
amoxiclav (amoxicillin/clavulanate). The finding that SHV-5 β-lactamase was the most 
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prevalent in our collection of uropathogenic E. coli isolates is in concordance with previous 
investigations of ESBL in Croatia [46-47].  The identification of SHV-2 and SHV-5 β-
lactamases enables us to speculate on the evolutionary sequence of SHV type ESBLs; from 
SHV-2 to SHV-5, according to the mutation process. Since there is only one amino acid 
substitution(Gly240→Lys) it can be hypothesized that in this hospital the mutation process 
took place in E. coli from SHV-2 to SHV-5 and from SHV-2a to SHV-12.  The similar 
phenomenon was previously described in Mexican pediatric hospital in K. pneumoniae strain 
[45]. CTX-M β-lactamases were identified in only two of 77 strains and were both of the 
same type (CTX-M-3). The presence of IS26 insertion sequence upstreams of the gene 
facilitates the expression of blaCTX-M gene and is important for the mobilization of blaCTX-M 
genes.  Thus, the by far most prevalent ESBL found in E. coli isolates in Croatia was SHV-5, 
which is in contrast with reports from many other countries in which CTX-M β-lactamases 
appear to be the most frequent type [6-13].  Recent studies found very high prevalence of 
CTX-M β-lactamases in Croatia which reached 60% in hospital isolates of K. pneumoniae 
[48] and 4.9% in community samples [49]. However, there are no published data on the 
prevalence of the CTX-M β-lactamases in the hospital where the study was conducted.  The 
resistance phenotype of two CTX-M positive strains was consistent with CTX-M β-
lactamases. The MICs of ceftazidime were below the susceptibility breakpoint in contrast to 
cefotaxime and ceftriaxone MICs which were high (>512 mg/L). Contrarily, to previous 
reports [7] the both strains were susceptible to β-lactam/inhibitor combinations. There were 
no significant difference in the prevalence of SHV, TEM and CTX-M- ESBLs in the neonate 
and infants group. TEM-E2 β-lactamase, a ceftazidimase found in one of our strains was 
previously reported from UK [50].  Strains containing only TEM-1 or TEM-2 β-lactamase 
most probably have some other resistance mechanism to expanded-spectrum cephalosporins 
such as production of rare type ESBLs for instance IBC or VEB β-lactamase, loss of porins or 
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production of plasmid-mediated AmpC β-lactamases. Since those strains were susceptible to 
cefoxitin and to inhibition by clavulanate it is not likely to expect that they harbour plasmid–
mediated AmpC β-lactamases. However, the clarification of these resistance mechanisms 
requires further testing, but this was beyond the scope of this study.  
According to the results of the study, SHV-5 producing UPEC strains were frequently 
clonally related and associated with breakouts in contrast to strains producing SHV-2, SHV-
2a, SHV-12 and CTX-M-3 β-lactamases, which were usually single isolates without tendency 
to spread throughout the hospital wards. The fact that the strains were clonally related and 
show similar resistance phenotypes points out that there is endemic and epidemic spread of 
SHV-5 producing E. coli in University hospital Split probably due to the insufficient infection 
control measures. Clustering of the E. coli isolates sustains the hypothesis of either patient to 
patient transmission of strains or a common source acquisition.  The fact that genotypically 
related strains persisted over years raises the possibility that these strains may have persisted 
unnoticed in the pediatric units on the hospital, which served as a source of patient 
contamination. Our data document the emergence of E. coli strains producing SHV-5 β-
lactamase arising from the horizontal transfer of blaSHV-5 genes and clonal dissemination of 
the strains.  All strains were obtained from pediatric units and neonatal wards indicating a 
localized dissemination within the hospital and pointing to a potential source of spread of an 
SHV-5 encoding plasmid in the hospital.  Spread of SHV-5 producing E. coli strains 
throughout the hospital units could be due to the selection pressure of cefazidime which is 
widely prescribed in our hospital and favours survival of the strains possessing mutation at the 
Ambler position 240 responsible for ceftazidime and aztreonam resistance. Hospital hygiene 
measures should be employed and the consumption of expanded-spectrum cephalosporins in 
the Split University Hospital should be restricted in order to reduce the spread of ESBL 
producing E. coli isolates throughout pediatric units. Since plasmids encoding ESBLs also 
  17 
 
contain resistance genes for aminoglycosides it is possible that consumption of these 
antibiotics could also exert the selection pressure which favours the spread of plasmids with 
ESBL genes.  
Carbapenems are the antibiotics of choice for the treatment of infections caused by the SHV-5 
producing E. coli strains isolated from children. Despite there is no fluoroquinolone resistance 
observed ciprofloxacin could not be considered as treatment choice in children age group. All 
strains were susceptible to combination of ceftazidime and clavulanate but in general β-lactam 
combinations with inhibitors are not recommended for the therapy of infections caused by 
ESBL producing bacteria due to pronounced inoculum effect and possibility of developing 
mutants hyperpoducing ESBL during therapy [51]. Cefoxitin exhibited good in vitro 
antibacterial activity against our ESBL producing E. coli but it is not recommended for the 
therapy of UTIs because it does not achieve high concentrations in urine.  The fact that all 
strains are fully susceptible to ciprofloxacin is probably due to the policy of not prescribing 
fluoroquinolones in children because of  their side effects on bone growth.  
The second goal of the study was the analysis of the virulence of ESBL strains isolated in 
neonates and older children. The strains predominantly produced hemolysin and were 
resistant to serum bactericidal activity, and the distribution of those virulence determinants 
did not differ significantly between the two studied groups of children. However, adhesin 
expression was detected in less than 50% of the strains and was especially rare in the strains 
isolated from neonatal urine samples. Among 34 adhesin-positive strains, six in neonate and 
28 in older children group, only 14 strains were P-fimbriated, almost exclusively detected in 
the infants group and in strains in which blaTEM-1 gene was detected. This is in concordance 
with the fact that in older children and adults, most UTIs are thought to occur by the 
ascending route, and bacterial adherence ability is very important first step in the pathogenesis 
[18]. By adhering to the urinary tract epithelium bacteria resist the urine flow enabling them 
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to persist and invade the tissues. Less frequently, blood-borne infection of the kidney occurs. 
It is well known that serum-resistance plays a key role in E. coli survival in blood. In neonates 
it is more likely that hematogenous invasion of the kidney can cause UTI, which could be the 
explanation for the high frequency of serum-resistant strains isolated in neonatal group but 
can not explain the high frequency of serum-resistant strains isolated in older children. The 
ESBL strains which were spread in the Split University Hospital in studied period were 
predominantly SHV and hemolysin producers and were resistant to serum bactericidal 
activity. The observed associations between the detection of bla genes and expression of 
certain virulence characteristics need additional studies. In the ten years since the study was 
done, infection control practices have changed and the antimicrobial prescribing practices 
have actually altered. As a consequence of that, the proportion of ESBL producing E. coli in 
paediatric and neonatology unit has decreased decreased from 14% in 2003 to 6% in 2011.  
Conclusions based on the results of the study was that hygienic regulation, reduction of 
antibiotic consumption and surveillance networks should be recommended in order to limit 
the spread of ESBL positive E. coli in the hospital departments involved. 
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Table 1.Primers used in this study 
 
Bla gene Primer  Sequence Annealing  
temp. 
Amplicon 
size (bp) 
Reference 
SHV MN-¸1  5’- CGC- CGG- GTT- ATT –CTT- ATT- TGT CGC-3’ 58° 
 
1016 
25 
MN-2 5’- TCT -TTC- CGA-TGC- CGC- CGC- CAG- TCA-3’ 
TEM OT-3 5'-ATG-AGT-ATT- CAA-CAT-TTC-CG-3’ 58° 
 
850 
26 
OT-4 5'-CCA-ATG-CTT-AAT-CAG-TGA-GG-3' 
CTX-M MA-1 5’-SCS-ATG-TGC-AGY-ACC-AGT-AA-3’ 55° 
 
554 
27 
MA-2: 5’-CGC-CRA-TAT-GRT-TGG-TGG-TG-3’ 
CTX-M- 1 M1-F 5’-AAA-AAT-CAC-TGC-GCC-AGT--TC-3’ 52° 415 29 
M1-R 5’-TTG-GTG-ACG-ATT-TTA-GCC-GC-3’ 
CTX-M- 2 M2-F 5’-CGA-CGC-TAC-CCC-TGC-TAT-T--3’ 52° 
 
552 29 
M2-R 5’-CCA-GCG-TCA-GAT-TTT-TCA-GG-3’ 
CTX-M-. 8 M8-F 5’-TCG-CGT-TAA-GCG-GAT-GAT-GC 
 
52° 666 29 
M8-R 5’-AAC-CCA-CGA-TGT-GGG-TAG-C-3’ 
 
52° 
CTX-M- 9 M9-F 5'-CAA-AGA-GAG-TGC-AAC-GGA-TG 52° 205 29 
M9-R 5'ATT-GGA-AAG-CGT-TCA-TCA-CC 
CTX-M -25 M25-F 5’-GCA-CGA-TGA-CAT-TCG-GG-3’ 52° 325 29 
M25-R 5’-AAC-CCA-CGA-TGT-GGG-TAG-C-3’ 
 
PER PER-
EXT-1-F 
5' GGG- ACA -R TC-SKA-TGA-ATG-TCA 52° 
966 
28 
PER-
EXT-1-R  
5' GGG- YSG- CTT-AGA- TAG- TGC –TGA-T 
IS26 IS26-F  5’-GCG-GTA-AAT-CGT-GGA-GTG-AT-3’ 52° 
 
400 
27 
IS26-R  5’-ATT-CGG-CAA-GTT-TTT-GCT-GT-3 
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Table 3. Cumulative MIC values and percentage of resistant isolates. 
 
Antibiotic and CLSI 
breakpoint 
MIC range MIC50 MIC90 % resistance 
Amoxycillin (32) 128-≥1024 ≥1024 ≥1024 100 (77/77) 
Amoxycillin/clavulanate 
(32/16) 
4-64 8 32 12. 98 (10/77) 
Cefazoline (32) 16-≥1024 256 ≥1024 97.40 (75/77) 
Cefuroxime (32) 8-≥1024 64 ≥1024 80.51 (62/77) 
Ceftazidime (32) 4-≥1024 256 ≥1024 89.61 (69/77) 
Ceftazidime/clavulanate 0.06-4 0.5 2 0 (0/77) 
Cefotaxime (64) 1-256 16 64 22.07 (17/77) 
Ceftriaxone (64) 2-≥1024 64 128 55.84  (43/77) 
Ceftibuten (32) 0.12-256 4 64 20.07 (16/77) 
Cefepime (32) 0.06-512 16 64 37.66 (29/77) 
Cefoxitin (32) 2-8 2 8 0 (0/77) 
Imipenem (16) <0.008-0.5 0.25 0.25 0 (0/77) 
Meropenem (16) 0.016-0.06 0.03 0.03 0 (0/77) 
Gentamicin (16) 2-512 64 256 92.20 (71/77) 
Netilmicin (32) 0.5-256 32 128 74.02 (57/77) 
Ciprofloxacin (8) ≤0.008-2 ≤0.008 0.03 0 (0/77) 
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Dice (Opt:0.50%) (Tol 3.0%-3.0%) (H>0.0% S>0.0%) [0.0%-100.0%]
PFGE01
1
0
0
8
0
6
0
4
0
2
0
0
PFGE01
1
45
31
6
5
83
81
76
77
69
68
73
59
78
57
10
9
37
43
42
41
40
89
39
44
38
90
49
87
95
93
92
67
65
85
48
46
62
61
98
35
34
33
30
53
52
27
26
60
08.02.2002
28.01.2002.
23.07.2002.
25.03.2002.
07.03.2002.
18.05.2003.
10.05.2003.
12.02.2002.
24.02.2003.
02.01.2003.
23.12.2002.
29.01.2003.
20.06.2003.
14.02.2003.
27.06.2003.
26.04.2002.
24.04.2002.
01.07.2002.
25.07.2002.
23.07.2002.
10.07.2002.
11.07.2002.
15.09.2003.
09.08.2002.
25.07.2002.
14.08.2002.
23.09.2003.
14.09.2002.
12.05.2003.
03.11.2003.
12.10.2003.
09.12.2003.
19.12.2002.
19.11.2002.
08.05.2003.
16.09.2002.
10.07.2002.
05.11.2002.
26.10.2002.
13.12.2003.
12.08.2002.
23.07.2002.
19.08.2002.
19.08.2002.
23.09.2002.
30.09.2002.
09.09.2002.
29.05.2003.
28.10.2002.
Neonatology
Pediatric
Pediatric
Pediatric
Pediatric
Pediatric
Pediatric
Pediatric
Pediatric
Pediatric
Pediatric
Pediatric
Pediatric
Pediatric
Pediatric
Pediatric
Pediatric
Pediatric
Neonatology
Pediatric
Pediatric
Pediatric
Pediatric
Neonatology
Neonatology
Neonatology
Neonatology
Neonatology
Neonatology
Pediatric
Pediatric
Neonatology
Pediatric surgery
Neonatology
Pediatric
Neonatology
Pediatric
Pediatric
Neonatology
Pediatric
Neonatology
Neonatology
Neonatology
Neonatology
Neonatology
Pediatric
Pediatric
Pediatric
Pediatric  
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26
60
58
29
50
64
56
55
20
19
24
23
22
18
17
25
15
14
13
12
72
70
51
11
82
84
86
97
36
28
29.05.2003.
28.10.2002.
15.10.2002.
02.07.2002.
29.01.2002.
25.11.2002.
07.10.2002.
04.07.2003.
04.06.2002.
03.10.2002.
10.07.2002.
10.07.2002.
29.04.2002.
11.05.2002.
23.09.2002.
11.07.2002.
06.05.2002.
27.04.2002.
20.05.2002.
30.05.2002.
27.01.2003.
07.01.2003.
16.09.2002.
30.06.2002.
17.03.2003.
17.03.2003.
15.04.2003.
29.11.2003.
02.07.2002.
26.06.2002.
Pediatric
Pediatric
Pediatric
Pediatric
Pediatric
Pediatric
Neonatology
Pediatric
Pediatric
Pediatric
Pediatric
Pediatric
Neonatology
Neonatology
Neonatology
Pediatric
Neonatology
Neonatology
Neonatology
Pediatric
Pediatric
Pediatric
Pediatric surgery
Neonatology
Pediatric
Pediatric
Pediatric
Pediatric
Pediatric
Pediatric
 
 
 
Figure 1.  
Pulsed field gel electrophoresis of genomic DNA. Date of isolation and hospital ward are 
shown. Isolates were considered to be identical if they showed 100% similarity and were 
considered clonally related if they showed greater than 80% similarity (differend in less than 
three bands). 
